Cipla CFO says drug maker to outperform domestic market in FY22, Moderna vaccine import may take time

Cipla CFO says drug maker to outperform domestic market in FY22, Moderna vaccine import may take time In an interview to Moneycontrol, Cipla#39;s Global Chief Financial Officer Kedar Upadhye expressed confidence that the company will outperform domestic formulation market and clock EBITDA margins of 22.5–23 percent for FY22.

No comments:

Post a Comment